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ABSTRACT
Several lines of evidence implicate BDNF in the pathophysiology of psychiatric illness. 
BDNF polymorphisms have also been associated with the risk of schizophrenia and mood
disorders. We therefore investigated whether levels of (pro)BDNF and receptor proteins, 
TrkB and p75, are altered in hippocampus in schizophrenia and mood disorder and whether 
polymorphisms in each gene influenced protein expression. Formalin-fixed paraffin-
embedded hippocampal sections from subjects with schizophrenia, major depressive disorder 
(MDD), bipolar disorder (BPD) and non-psychiatric controls were obtained from the Stanley 
Foundation Neuropathology Consortium. (pro)BDNF, TrkB(T1) and p75 protein densities 
* Manuscript
2were quantified by immunoautoradiography and DNA extracted from each subject was used
to determine the effect of genotype on protein expression. In MDD, reductions in (pro)BDNF 
were seen in all layers of the right but not the left hippocampus with no changes in the 
dentate gyrus. The pattern was similar but less marked for BPD. In addition, BPD but not 
MDD patients, had bilateral reductions in p75 in hippocampal layers but not in dentate gyrus. 
No changes in TrkB(T1) density were seen in any diagnosis. These findings suggest MDD 
and BPD may share impairment in (pro)BDNF expression. However, BPD may involve
impairments of both (pro)BDNF and p75 receptor, whereas MDD may involve impaired
(pro)BDNF alone. Moreover, the lateralisation of changes may indicate a role of asymmetry 
in vulnerability to MDD. Hippocampal (pro)BDNF and receptor levels were also affected by 
genotype, suggesting that allelic variations are important in the hippocampal abnormalities
seen in these psychiatric disorders.   
INTRODUCTION
Hippocampal volume reduction is one of the most consistent changes reported in structural 
MRI studies of schizophrenia (Nelson et al 1998; Wright et al 2000) and mood disorders 
(Videbech and Ravnkilde 2004). Postmortem studies suggest that hippocampal volume 
reduction in schizophrenia and possibly mood disorders may be a consequence of decreased 
neuropil and cell size rather than neuron loss (Harrison 2002; Harrison 2004; Heckers and 
Konradi 2002). As neurotrophins are important in the development and maintenance of 
neural connectivity in the hippocampus (Huang and Reichardt 2001; Lewin and Barde 1996),
impaired neurotrophin function may be an important potential mechanism for loss of neuropil 
in psychosis and mood disorder (Hashimoto et al 2004; Thome et al 1998). 
Brain-derived neurotrophic factor (BDNF) and its precursor, proBDNF, and receptors TrkB
(coded by NTRK2) and p75 (coded by NGFR), are expressed in both the developing and 
adult hippocampus and also in other CNS regions implicated in schizophrenia and mood
disorders (Allen et al 1994; Harrison 1999; Harrison 2002; Ozbas-Gerceker et al 2004;
3Romanczyk et al 2002; Webster et al 2002, 2006; Yang et al 2009). BDNF is also involved in 
the development and function of neurochemical systems that may be altered in these illnesses 
(Djalali et al 2005; Guillin et al 2004; Harrison 1999; Lessmann 1998). Impaired BDNF 
function could thus result in failure to develop and effectively maintain such neurotransmitter 
systems. Allelic variations may also affect BDNF and hippocampal function (Egan et al 
2003; Miyajima et al, 2007) and may be associated with schizophrenia and mood disorders 
(Levinson 2006; Neves-Pereira et al 2005; Neves-Pereira et al 2002; Sklar et al 2002; 
Szekeres et al 2003).
Decreased hippocampal BDNF mRNA has been reported in animal models of schizophrenia 
and mood disorders (Angelucci et al 2005; Ashe et al 2002; Lipska et al 2001). However, 
postmortem studies of hippocampal BDNF mRNA and protein in subjects with schizophrenia 
have yielded inconsistent results (Brouha et al 1996; Chen et al 2001; Durany et al 2001; 
Iritani et al 2003; Knable et al 2004; Takahashi et al 2000; Webster et al 2004, personal 
communication). Reductions in hippocampal TrkB protein and mRNA have been reported in 
single studies (Iritani et al 2003 and Takahashi et al 2000, respectively), particularly in the 
hilus (Webster et al 2004, personal communication). Inconclusive results have also been 
reported in postmortem studies of BDNF and TrkB in MDD and BPD subjects (Chen et al 
2001; Knable et al 2004; Webster et al 2004, personal communication). There have been no 
expression studies of (pro)BDNF or the p75 receptor in schizophrenia or mood disorders. 
Using hippocampal tissue from four groups (controls, schizophrenia, MDD and BPD), 
(pro)BDNF, TrkB and p75 protein density was quantified. In addition, DNA extracted from 
frozen cerebellum was used to determine whether polymorphisms within each gene 
influenced hippocampal protein expression.  
4METHODS AND MATERIALS
Postmortem Brain Samples
Formalin-fixed paraffin-embedded anterior hippocampal sections (10 µm)and frozen (-80º C) 
blocks of cerebellum were obtained from the Stanley Foundation Neuropathology 
Consortium which consists of subjects with schizophrenia, MDD, BPD and age and gender 
matched control subjects (n = 15 per group; however two cases were missing from the 
control group, resulting in n of 13). Frozen hippocampus from two cases were also obtained 
from the Stanley Consortium for characterising the specificity of antibodies using Western 
blotting. Diagnoses were retrospectively established by two senior psychiatrists using DSM-
IV criteria. Detailed clinical information and diagnostic procedures are provided elsewhere 
(Dowlatshahi et al 1999). 
Western blots
Frozen hippocampus from two cases obtained from the Stanley Consortium was 
homogenised in tris-HCl-sucrose buffer with a protease inhibitor cocktail (Sigma, UK) and 
centrifuged at 4°C at 13000 rpm for 10 minutes. For (pro)BDNF (1:200; sc-546, Santa Cruz) 
and TrkB (1:500; MAB397, R&D Systems) antibodies, proteins were separated on 14% and 
7% SDS gel respectively under reducing conditions, and transferred to a PVDF membrane 
which was incubated with the diluted primary antibody overnight at 4°C, then with anti-
rabbit (BDNF 1:4000) or anti-mouse (TrkB 1:2000) IgG peroxidase-labelled secondary 
antibody. For the p75 antibody (1:67; MAB367, R&D Systems), proteins were separated on 
5an 11% SDS gel under non-reducing conditions, transferred to a PVDF membrane which was 
incubated with the primary antibody overnight at 4°C, and then with anti-mouse IgG 
peroxidase-labelled secondary antibody (1:1000 dilution). Prior to incubations, all 
membranes were treated with TTBS (pH 7.4) blocking buffer (10mM Tris, 0.9% NaCl, 1% 
Tween-20 and 5% milk powder) for 1 hour at room temperature. Detection was achieved 
through the enhanced chemiluminescent (ECL) method (Amersham Biosciences, UK).
Immunoautoradiography
Two brain sections per case and per antibody were used for immunoautoradiography as 
described previously (Toro and Deakin, 2005). Briefly, sections were deparaffinised in 
xylene and rehydrated in an ethanol series. Sections were microwaved in citrate buffer (pH 
6.0) for 20 minutes for antigen retrieval. Non-specific binding was blocked using 10% 
normal donkey/sheep serum (1.5 hours). This was followed by application of the antibody 
diluted in 0.1M phosphate-buffered saline (PBS) with 1% normal donkey/sheep serum and 
0.3% Triton X-100. Primary antibody incubations at the following dilutions: BDNF (1:50), 
TrkB (1:60) and p75 (1:10), were carried out for 20 hours at 4°C. Sections were then washed 
in 0.1M PBS (3x10 minutes) and incubated at room temperature with 0.1µCi/µl Sulphur-35-
labelled secondary antibody (1:800; Amersham, UK) for 1.5 hours. Finally, sections were 
washed in 0.1M PBS, air-dried and exposed to autoradiographic film (Kodak Biomax MR) 
for 6 days. Negative control sections were obtained by omitting the primary antibody.
Genotyping
6All 60 subjects were genotyped for several SNPs located within the BDNF, NTRK2 and 
NGFR genes (table 6). SNP selection was based on a combination of haplotype-tagging 
strategy and SNPs reported in previous schizophrenia, mood disorder and behavioural 
association studies (Adams et al 2005; Egan et al 2003; Haga et al 2002; Kunugi et al 2004; 
Levinson 2006; Miyajima et al, 2007; Neves-Pereira et al 2005; Neves-Pereira et al 2002; 
Sklar et al 2002; Strauss et al 2004; Szekeres et al 2003), and criteria including validation by 
frequency and location within the gene. 
Genomic DNA was extracted from frozen cerebellum using a modified version of a 
previously described method (Freeman et al 2003) that included 17 hour incubation in 
0.5mg/ml proteinase K (Fisher Scientific, UK). Genomic DNA was resuspended in TE 
(10mM Tris-HCL, 1mM EDTA, pH 8), normalized to 5-10ng/µl and stored at -20°C. 
Genotyping was performed using iPLEX™ chemistry on a MALDI-TOF Mass Spectrometer 
(Sequenom Inc., San Diego, CA, USA). PCR was performed with 5-10ng of genomic DNA, 
1.63mM MgCl2, 0.1U Hot Start Taq polymerase, Hot Start Taq PCR buffer (1.25X), 100nM 
forward and reverse PCR primers, 500μM dNTPs and nuclease-free water in a total volume 
of 5μl. PCR thermal cycling was performed on a Peltier thermal cycler (PTC–225, MJ 
Research) at 95°C for 15 minutes, (95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 
60 seconds) for 45 cycles, and finally 72°C for 3 minutes. Dephosphorylation of 
unincorporated dNTPs was achieved by adding 2μl Shrimp Alkaline Phosphatase and buffer 
(0.3μl SAP enzyme, 0.17μl hME buffer and nuclease-free water) to PCR products, and 
incubating at 37°C for 20 minutes, followed by inactivation for 5 minutes at 85°C. The 
primer extension PCR reaction was performed in a final 9µl volume extension reaction 
containing 7µl of the cleaned product, 0.2µl of iPLEX termination mix, 0.2µl iPLEX buffer, 
0.8µl primer plex, 0.04µl iPLEX enzyme and 0.76µl nuclease-free water. Samples were 
7denatured at 94°C, strands annealed at 52°C for 5 seconds and extended at 80°C for 5 
seconds. This was repeated four more times and then looped back to a 94°C denaturing step 
for 5 seconds, before entering the five cycle annealing and extension loop again. The five 
annealing and extension steps with the single denaturing step were repeated an additional 39 
times. A final extension was done at 72°C for 3 minutes. The iPLEX reaction products were 
desalted and dispensed onto a 384-well SpectroChip (Sequenom Inc.), processed and 
analysed in a mass spectrometer by MassARRAY Workstation (version 3.3) software 
(Sequenom Inc).
Method of analysis
Immunoautoradiography 
Immunoautoradiographic images on all films were scanned at a resolution of 1000 pixels per 
inch using an A3 flatbed scanner (Microtek Scan Maker 9600xl). Using Bioquant Nova 
Prime analysis software and blind to diagnosis, optical density measurements were taken 
from the molecular layer (ML), granule cell layer (GCL) and hilus of the dentate gyrus and 
from stratum oriens (SO), pyramidal layer (PL) and stratum radiatum (SR) from CA1 to 
CA3. This was done for each antibody. However, some subregions could not be measured 
due to occasional artefacts on the autoradiographic films which affected a maximum of four 
subregional measures for p75, seven subregions for (pro)BDNF and sixteen subregions for 
TrkB-T1. The tables show data for all measures taken. The statistical analysis and the figures 
showing statistical effects include only cases with measures in all subfields. Absolute density 
was determined using a standard curve generated from optical density measurements of 14C 
8plastic standards. Sections were allocated to one of 6 anterior-posterior (AP) levels on the 
basis of the conformation of the GCL. 
Statistical analysis
Immunoautoradiography
Data analyses were performed with SPSS v14.0 software (SPSS, Chicago, Illinois). All 
values are mean ± standard error (SEM) density. Effect of postmortem interval (PMI), brain 
pH, age and months in formalin were assessed by Spearman’s correlations in every subregion
and every diagnostic group prior to the main analysis. Variables showing significant 
correlations were included as covariates in the main analysis.
Repeated measures analysis of variance (RM ANOVA) was used to identify overall effects 
of diagnosis (between subjects) and its interaction with subregion (within subjects) and side 
(left v right). Significant main effects of diagnosis (p ≤ 0.1 confirmed by univariate Huyhn-
Feldt corrected p < 0.05) were investigated by planned post-hoc contrasts. Significant
interactions of diagnosis with subregion were investigated using multivariate ANOVA of 
subregion. This allowed the effects of diagnosis to be examined separately in each subregion, 
with planned comparisons within a single analysis.  
To detect lateralised changes, side was included as a between subjects factor (only one 
hemisphere was fixed from each brain) and was included in the analysis if there was a 
significant effect or interaction with diagnosis. The possible influence of anterior-posterior 
9(AP) level (of the anterior hippocampus sections) on protein expression was investigated by 
including it as a covariate.  
Fluphenazine equivalents were used to determine effects of antipsychotic treatment. 
Correlations of protein density with antipsychotics, age at onset and duration of illness were 
evaluated by Spearman’s rank order correlation within and across diagnostic groups, 
excluding controls. Effects of antidepressants, lithium, suicide, side and sex, were evaluated 
by re-running the repeated measures ANOVA with an additional 2-level drug, suicide, side 
or sex grouping factor. Controls were excluded from drug and suicide analysis since none 
were medicated and none committed suicide. To reproduce the analyses of antidepressant 
effects of Chen et al (2001) and Webster  et al (2004) we additionally compared: i) all 
subjects on antidepressants with those off ignoring diagnosis although this risked the 
confound that all controls would be in the antidepressant group; and ii) controls vs patients 
on and off antidepressants (ie 3 groups).   
Genotyping
Chi-squared tests were performed for each SNP assay to test for deviation from Hardy-
Weinberg equilibrium and genotypic comparison was carried out using the dominant effect 
model. Potential stratification problems due to unequal representation of ethnic groups were 
not relevant to our sample, as all but one subject were white Caucasian. Subjects 
homozygous and heterozygous for the minor allele were grouped together and compared with 
subjects that were homozygous for the major allele. Mean (±SEM) protein density per 
subregion was compared between the two groups. Differences in mean protein density 
associated with genotype, regardless of diagnosis, were analyzed using RM ANOVA to 
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avoid artefacts of multiple comparisons (SPSS v14.0). The between-subjects factor was 
genotype (2 levels). The within-subjects factor was subregion (5/6 levels). Only main effects 
of genotype are considered significant since this indicates the effect of genotype is 
independent of subregion. Although not strictly necessary, separate t-tests were carried out to 
confirm effects of genotype in individual subregions. For all SNPs, mean differences 
between genotype groups, with regards to covariates (PMI, months in formalin and brain 
pH), were analysed with t-tests.
RESULTS
Western Blots
For the BDNF antibody, a 35kDa band corresponds to the precursor form of BDNF -
(proBDNF), and a 42kDa band may correspond to a trimeric form of mature BDNF (Spires et 
al 2004). We have signified this co-reactivity as (pro)BDNF. For the TrkB antibody, a 95kDa 
band corresponds to the truncated isoform - TrkB T1, and a 116kDa band may correspond to 
a modification of either of the receptor isoforms (Connor et al 1996). We have signified this 
co-reactivity as TrkB (T1). For the p75 antibody, a single band was observed at 75kDa which 
corresponds to the p75 receptor. No bands were observed when each of the antibodies was 
omitted (figure 1).  
(Figure 1 here)
(Pro)BDNF, TrkB (T1) and p75 Immunoautoradiography
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Immunoautoradiographs (figure 2) show that the p75 density pattern appears partially 
complementary to (pro)BDNF density pattern. Within the CA axonal and dendritic layers 
(SO and SR), (pro)BDNF density is relatively high and p75 density is relatively low. In the 
GCL and PL, (pro)BDNF density is relatively low and p75 density relatively high. 
(pro)BDNF and p75 density is similar in the hilus and ML. TrkB (T1) density is generally 
lower than both (pro)BDNF and p75, in agreement with previous reports of low levels in 
adult human hippocampus (Webster et al 2006). 
Figure 2 here.
Table 1 here
Effect of demographic and perimortem variables on protein density
In some subregions, greater months in formalin were significantly associated with decreased 
(pro)BDNF density but it was not a significant covariate in the overall analysis. Results 
without co varying for months in formalin are presented. However, all significant results 
were also significant with formalin as a covariate. There were no significant effects of 
potential confounds on TrkB (T1) and p75 density.
Effect of diagnosis on hippocampal (pro)BDNF density 
Table 2 shows (pro)BDNF density (mean ± SEM) in individual hippocampal subregions of 
all diagnostic groups. A general decrease in (pro)BDNF density can be seen in the mood
disorder groups. However, the main effect of diagnosis was not significant because the effect 
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of diagnosis depended on hippocampal subregion and side of the sample (diagnosis x 
subregion x side interaction, p = 0.005 and p= 0.03 after covarying for time in formalin). The 
multivariate analysis showed the interaction was due to effects of diagnosis in SO, PL and 
SR (figure 3) and the absence of effects in the dentate gyrus (ML, GCL/hilus; see table 2). 
Diagnosis x side interactions were significant in SO (p=0.002) and SR (p=0.02) and they 
remained of statistical interest after covarying for time in formalin (p=0.01 and 0.06
respectively). In both layers, the interaction arose principally from reduced (pro)BDNF in 
right hippocampus from MDD subjects and to a lesser extent from the BPD group (figure 3)
as revealed by separate multivariate ANOVAs for right and left sides. No differences from 
controls were seen in any subregion in the left hippocampus but highly significant reductions 
were seen in the right hippocampus in all three CA layers from MDD subjects (all p<0.01) 
and in right SO and SR of BPD subjects (both p<0.03). Furthermore, within the MDD group, 
(pro)BDNF densities in the right hippocampus were markedly reduced compared to the left 
in all three CA layers (SO and SR p=0.001 and PL p=0.11; 2-tailed t-tests). No left-right 
comparison in the other groups approached significance. 
More anterior sections had greater (pro)BDNF density across all layers than posterior 
sections (see table 3). However, anterior and posterior sections were evenly distributed across 
groups and including it as covariate did not affect the statistical significance. 
Table 2 here
Table 3 here
Figure 3 here
Figure 4 here.
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Effect of diagnosis on hippocampal TrkB (T1)and p75 density 
Table 4 shows TrkB (T1) density (mean ± SEM) in individual subregions of all diagnostic 
groups. There was no main effect of diagnosis or AP level and no interactions of diagnosis
with side or layer.
Table 4 here
Table 5 shows p75 density (mean ±SEM) in individual subregions of all diagnostic groups. 
In every subregion, BPD subjects had lowest densities whereas MDD subjects had slightly 
greater densities, except in the granule cell layer. The overall effect of diagnosis was of 
borderline statistical significance (p=0.1) with or without formalin as a covariate. This was 
due to lower p75 values in BPD compared to MDD (p=0.02), schizophrenia (p=0.09) and 
control groups (p=0.18). No other group differences approached statistical significance.  This 
pattern was seen to a significantly greater effect (diagnosis by subregion interaction p=0.02, 
RM ANOVA) in SO (p=0.02) and to some extent in PL and SR, than in the dentate gryus 
layers (p>0.1). In SO, PL and SR, p75 reductions in BPD compared to the MDD group were 
all statistically significant (table 5). Reductions in BPD compared to the schizophrenia group 
were significant in two of the three layers and reductions compared to controls were trend 
significant (p=0.1), also in two layers. 
Table 5 here. 
Figure 5 here
Effect of drug treatment and suicide on protein expression
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No effect of suicide, antipsychotic, antidepressant or lithium treatment was observed on 
(pro)BDNF, TrkB (T1) and p75 density in the main analyses. In the further analyses of 
antidepressant effects on (pro)BDNF, there were no trends to significance in those on (n=20) 
and off (n=31) antidepressants in any subfield or overall. Compared to controls, patients on 
(n=20) and off (n=21) antidepressants both tended have lower (pro)BDNF levels (p=.04 and 
p=.09 respectively) with no trends to significance between the patients on and off 
antidepressants. Within the MDD group there were no trends to increases in (pro)BDNF in 
the treated depressives (n=6 off vs 8 on) in any subfield or overall.  
Effect of genotype on protein expression
Allele and genotype frequencies and chi-squared and p-values for nine, eight and fourteen 
SNPs for BDNF, NGFR and NTRK2 respectively were calculated. A summary of these are 
available by request from the authors. (pro)BDNF density was reduced in those subjects who 
carried the minor allele of SNPs rs12273363 and rs7127507 (main effect of genotype, p = 
0.05; figure 5). TrkB (T1) density was decreased in subjects who carried the minor allele of 
NTRK2 SNPs rs1187323 and rs1187326 (main effect of genotype, p = 0.05; figure 6a). 
Reductions were seen in every subregion (figure 6c & 6d). p75 density was increased in 
subjects who carried the minor allele of rs11466117 (main effect of genotype, p = 0.03; 
Figure 6a). Increases were seen in every subregion (figure 7b).
Figure 6 here
15
DISCUSSION
Diagnosis-Specific Changes
In MDD, reductions in (pro)BDNF density were seen in the right hippocampal CA layers 
compared with right-sided controls and also when compared with left-sided MDD subjects. 
BPD subjects showed a similar but less marked pattern of right-sided changes. BPD subjects
also showed reductions in p75 receptor density across all subregions compared to the other 
groups. The findings raise the possibility that BPD and MDD both involve lateralised
impaired (pro)BDNF expression but that BPD additionally involves impaired p75 expression. 
(Pro)BDNF
The interpretation of any effects of diagnosis must be tempered by the probable co-reactivity 
of the BDNF antibody. Future studies using antibodies that can differentiate between 
(pro)BDNF and mature BDNF are thus necessary. There was a reduction in (pro)BDNF 
density in right-sided hippocampal CA sublayers in MDD and to a lesser extent in BPD.
Reductions in the ML and GCL/hilus were not statistically significant, in contrast to a study
of the Stanley Consortium database, in which a significant reduction was observed in the 
hilus in BPD (Knable et al 2004). However, two other studies of consortium brains found no 
differences in MDD or BPD using a quantitative immunohistochemical method (Chen et al 
2001) and in-situ hybridisation (Webster et al 2004, personal communication). However, in 
the latter study, subjects on antidepressant drugs at the time of death had similar levels of 
BDNF to unaffected controls, whereas those off antidepressant drugs had levels significantly 
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lower than controls. The present postmortem finding and others are compatible with the 
hypothesis from the animal literature that BDNF is involved in the pathophysiology and 
treatment of mood disorder. 
In schizophrenia, although mean (pro)BDNF densities were lower than controls in most
subregions, they did not reach significance. This is consistent with two previous studies
(Chen et al 2001; Webster et al 2004, personal communication), although Webster measured 
mRNA, not protein, and in CA subfields rather than layers. Reductions in hilus have been 
reported in schizophrenia (Knable et al 2004) but this was not seen in the present study, most 
likely due to the fact the antibody used in the present study was specific to (pro)BDNF and 
quantitative immunoautoradiography rather than immunohistochemistry was used. Further 
studies are necessary to clarify this discrepancy. Our results also fail to corroborate increases 
in BDNF reported previously (Iritani et al 2003; Takahashi et al 2000) using non-quantitative 
immunohistochemistry and immunoassay, respectively. The latter finding however, was not 
replicated using similar methodology (Durany et al 2001). In summary it would appear from 
postmortem studies that major changes in hippocampal BDNF expression are not found in
schizophrenia. 
The TrkB Receptor
The co-reactivity of the TrkB antibody used in this study warrants attention, as different 
functions have been postulated for the different TrkB isoforms (Baxter et al 1997; Biffo et al 
1995; Eide et al 1996). No significant differences versus controls or between diagnostic 
groups were seen for TrkB(T1). It is possible however that there might be group differences 
in TrkB isoforms that would not be revealed by this antibody. A role for both the full-length 
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and truncated receptor in depression and its treatment is implicated by findings from animal 
and postmortem studies (Nibuya et al 1995; Saarelainen et al 2003; Webster et al 2004, 
personal communication). Although Webster reported no change in MDD (and a reduction in 
hilus in BPD), they found that subjects on antidepressants at the time of death had similar 
levels of TrkB to controls, whereas those off antidepressants had levels significantly lower 
than controls. 
In schizophrenia, one study reported a 44% reduction of TrkB in hippocampal extracts
(Takahashi et al 2000). Others have reported a qualitative lack of TrkB-stained fibres (Iritani 
et al 2003) and a reduction in TrkB mRNA in the hilus (Webster et al 2004, personal 
communication). However, the present study casts doubt on the generality of a 44% 
reduction in schizophrenia.  
The p75 Receptor
In contrast to the several TrkB studies, there have been no previous postmortem studies of 
the p75 receptor in schizophrenia, MDD or BPD. Like BDNF and TrkB, it is expressed 
during development and in the adult brain and has a role in cell death/survival, axon 
elongation and synaptic plasticity (Dechant and Barde 2002). In the present study, p75 was 
reduced in BPD compared to other groups in all hippocampal layers but not in dentate. 
However, this only achieved full statistical significance in comparison to the MDD group and 
to the schizophrenia group in two layers. Reductions compared to controls were not far short 
of significance. Overall the results suggest that while impaired BDNF expression is common 
to both BPD and MDD, there may be additional involvement of the p75 receptor in BPD 
which is clearly not shared by the less severe illness, MDD. Evidence for a role of 
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(pro)BDNF in neuronal signalling was extended recently by the finding that (pro)BDNF is 
released by neurons (Yang et al, 2009). This finding warrants further exploration of 
(pro)BDNF and p75 in BPD.
Effect of Laterality
Interestingly, a meta-analysis of imaging studies of hippocampal volume in unipolar 
depression showed reductions in both left and right hippocampus, though reductions were 
greater in the right. Furthermore, the total number of depressive episodes was significantly 
correlated with right, but not left hippocampal volume reduction (Videbech and Ravnkilde 
2004). Two studies report that the antidepressant citalopram attenuates amygdalo-
hippocampal responses to fearful faces on the right side (Del-Ben et al 2005, Norbury et al 
2007). A comprehensive meta-analysis of amygdala activations in humans found evidence 
for a role of the right amygdala in rapid processing of visual emotional stimuli (Cosatfreda et 
al 2007). Therefore, right lateralised changes in BDNF signalling may determine 
vulnerability to mood disorder or could reflect the effect of stress. This may be right 
lateralised in humans because of hemispheric specialisation in emotion processing.
Drug Treatment
No effect of antipsychotic treatment on protein density was seen. However, data for 
antipsychotic treatment is expressed as fluphenazine equivalents. There were too few 
subjects to determine whether atypical antipsychotic drugs might differ from typical as 
suggested by animal studies (Bai et al 2003; Bai et al 2002; Chlan-Fourney et al 2002; Li et 
al 1999). BDNF may also be a mediator of both antidepressant and mood stabilizer action 
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(Chuang 2005; Hashimoto et al 2004). Despite the interesting findings from animal studies, 
there are few human studies of antidepressant effects on BDNF (Chen et al 2001; Webster et 
al 2004, personal communication). We were not able to confirm the antidepressant-
associated increases in BDNF seen in two studies despite studying the same brains and using 
the same respective analyses. However, as (pro)BDNF was measured in the present study, 
this is likely to contribute to the discrepancy.
Effect of Genotype
Five of the 31 SNPs examined were associated with changes in protein density across all 
hippocampal subregions. These SNPs are located primarily in 5′ UTR and intronic regions
and may affect protein levels by modulating gene expression, alternative splicing and protein 
translation mechanisms. These SNPs warrant further study in a larger cohort. 
Conclusion
This postmortem study suggests that impaired (pro)BDNF expression, especially in the right 
side, may be common to both MDD and BPD. The present findings further suggest BPD may 
involve an additional impairment of (pro)BDNF signalling through the p75 receptor. In BPD, 
persistent depression is a far greater problem than the typically infrequent episodes of mania. 
It is tempting to speculate that a combined impairment of (pro)BDNF and p75 receptor 
function in BPD relates to the chronicity of depression rather than the occurrence of mania, 
however further larger-scale studies are necessary to test this theory. This study also provides 
evidence of five novel functional SNPs within the BDNF, TrkB and p75 genes, which 
affected levels of their respective protein. Each of these SNPs may play a role in the 
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development of hippocampal abnormalities and may thus increase the risk of developing 
schizophrenia or mood disorders. Again, larger-scale studies are necessary to clarify the 
effects of BDNF, TrkB and p75 gene SNPs on BDNF and (pro)BDNF signalling.
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TITLES AND LEGENDS TO FIGURES
Figure 1 Title. Antibody Specificity
Figure 1 Legend. Western blots showing the specificities of the 
neurotrophin/receptor antibodies. The blots were incubated with (A) anti-BDNF, (B) 
anti-trkB, and (C) anti-p75; Negative control blots (i.e. without the respective 
antibodies) showed no signal (not shown).
Figure 2 Title. Immunoautoradiographs
Figure 2 Legend. Representative immunoautoradiographic images of anterior 
hippocampal sections from all three studies showing density pattern of A. 
(pro)BDNF, B. p75 and C. TrkB (T1). Bottom row shows respective negative control 
sections (i.e. omission of primary antibody).
Figure 3 Title. Effects of diagnosis, subfield and side for (pro)BDNF
Figure 3 Legend. (pro)BDNF density (mean ± SEM) in individual hippocampal 
subregions, left and right sides in all diagnostic groups ** p<0.01, * p<0.05 compared 
to controls (from multivariate analysis of right side samples). + p<0.01 right v left side 
in major depressives group. C – Controls; S - Schizophrenia; D - Major Depressive 
Disorder; B - Bipolar Disorder.
Figure 4 Title. p75 density in Stratum Oriens showing bilateral change in bipolar 
disorder
Figure(s)
Figure 4 Legend.  p <0.01 B = Bipolars vs D = depressed group; p <0.05 vs S  = 
schizophrenia group; p = 0.07 vs C = controls, bilateral contrasts from mulitvariate 
analysis.
Figure 5 Title. Influence of Genotype on Hippocampal Brain Derived Neurotrophic 
Factor Density.
Figure 5 Legend. BDNF density (mean ± SEM) in all hippocampal subregions 
together of subjects that are homozygous for the major allele versus subjects that are 
homo/heterozygous for the minor allele of BDNF SNP rs12273363 and rs712507
[* p < 0.05 (Repeated measures ANOVA)].
Figure 6 Title. Influence of NTRK2 and NGFR Genotype on hippocampal TrkB and 
p75 density.
Figure 6 Legend. (a) Receptor density (mean ± SEM) in all hippocampal regions of 
interest together of subjects that are homozygous for the major allele versus subjects 
that are homo/heterozygous for the minor allele of NGFR SNP rs11466117, and
NTRK2 SNPs rs1187323 and rs1187326 [* p < 0.05 (Repeated measures ANOVA)]. 
(b-d) Receptor density (mean ± SEM) in individual hippocampal regions of subjects 
homozygous for the major allele versus subjects homo/heterozygous for the minor 
allele of b) NGFR SNP rs11466117; c) NTRK2 SNP rs1187323; and d) NTRK2 SNP 
rs1187326. [** p < 0.01; * p < 0.05 (T-tests)]. ML - Molecular Layer; GCL - Granule 
Cell Layer; SO - Stratum Oriens; PL - Pyramidal Layer; SR - Stratum Radiatum.
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Table 1. Clinical and demographical data of Stanley Foundation 
Neuropathology Consortium (mean SEM).
Control Schizophrenia Major 
Depression 
Bipolar 
Disorder
N 13 15 15 15
Gender (F/M) 6/7 6/9 5/10 6/9
Age 47.9 (10.3) 44.5 (13.1) 46.5 (  9.3) 42.3 (11.7)
Age Onset n/a 23.2 (  8.0) 33.9 (13.3) 21.5 (  8.4)
Duration of 
Illness (yrs)
n/a 21.3 (11.4) 12.7 (11.1) 20.1 (  9.7)
PMI (hrs) 23.4 (  9.6) 33.7 (14.6) 27.5 (10.7) 32.5 (16.1)
pH   6.3 (  0.2)   6.2 (  0.3)   6.2 (  0.2)   6.2(  0.2)
MthForm   4.2 (  3.8) 11.2 (  8.5) †   8.4 (  6.6) †   9.7 (  3.6) †
Side (L/R) 7/6 9/6 9/6 7/8
Suicide   0   4   7   9
Antidepressants   0   5   8   7
Antipsychotics   0 15   0 12
Lithium   0   2   2   4
† - different from controls, planned contrast p<0.05. PMI - Postmortem Interval; MthForm -
Months in Formalin; F - Female; M - Male; L - Left; R - Right; Integers are numbers of 
cases.
Table 1
Table 2. Mean (± SEM) (pro)BDNF density (nCi/g/tissue) in individual 
hippocampal subregions of all 4 groups.
Layer Control N SCZ N MDD N BPD N
ML 234.0±29.3 10 210.3±26.7 12 191.8±24.8 14 199.5±23.9 15
GCL-HIL 337.3±29.7 10 290.9±27.2 12 305.8±25.1 14 277.3±24.3 15
SO b 627.6±31.0 11 532.7±27.5 14 539.4±27.5a 14 533.7±26.5a 15
SP c 296.2±30.6 11 236.8±28.2 13 183.9±27.1a 14 229.1±26.2c 15
SR c 461.6±32.4 11 357.5±28.7 14 405.4±28.7c 14 369.1±27.7b 15
a,b,c significance of main effect of diagnosis in each subregion and of planned contrasts vs 
control: a  p ≤ 0.01, b p ≤ 0.05, c p ≤ 0.1 from multivariate analysis.  SCZ - Schizophrenia; 
MDD - Major Depressive Disorder; BPD - Bipolar Disorder; N - Number; ML - Molecular 
Layer; GCL-HIL - Granule Cell Layer - Hilus; SO -  Stratum Oriens; SP – Stratum 
Pyramidale; SR - Stratum Radiatum. 
Table 2
Table 3. Mean (±SEM) Protein Density in Anterior and Posterior Hippocampal 
Sections 
Anterior N Posterior N
(pro)BDNF* 366.3±17.1 26 317.1±17.1 25
TrkB (T1) 73.2±5.5 22 71.2±6.1 18
P75 368.6±13.9 28 382.8±14.4 26
* Significant difference - p < 0.05 (Repeated Measures ANOVA). N - Number of Cases.
Table 3
Table 4. Mean (± SEM) TrkB (T1) density (nCi/g/tissue) in individual 
hippocampal subregions of all 4 groups.
Layer Control N SCZ N MDD N BPD N
ML 51.1±8.8 9 59.3±7.6 12 50.8±6.4 14 53.3±8.6 10
GCL 67.1±10.4 9 80.3±8.1 11 76.2±5.8 12 76.7±8.2 9
HIL 54.2±10.5 10 66.3±6.0 12 59.5±6.9 14 71.8±8.2 11
SO 102.3±8.7 10 110.7±11.7 13 99.1±10.7 14 109.9±10.9 11
SP 60.3±9.7 10 64.0±9.0 13 53.2±7.7 14 63.2±10.0 11
SR 67.2±7.6 10 73.2±9.2 13 62.9±7.5 14 70.0±8.4 11
SCZ - Schizophrenia; MDD - Major Depressive Disorder; BPD - Bipolar Disorder; N -
Number; ML - Molecular Layer; GCL - Granule Cell Layer; Hil - Hilus; SO - Stratum 
Oriens;  SP – Stratum Pyramidale;  SR - Stratum Radiatum. 
Table 4
Table 5. Mean (± SEM) p75 density (nCi/g/tissue) in individual hippocampal 
subregions of all 4 groups.
Layer Control N SCZ N MDD N BPD N
ML 340.5±21.3 11 339.3±18.9 14 360.4±18.2 15 307.2±18.2 15
GCL 435.7±22.5 11 453.1±19.4 14 441.5±19.3 14 407.8±18.6 15
HIL 346.3±20.7 11 356.3±18.3 14 372.9±17.7 15 327.0±17.7 15
SO b 426.5±28.4 10 424.7±24.0 14 467.6±23.2 15 357.9±23.2cdf 15
SP c 378.1±23.9 10 399.9±20.2 14 403.0±19.5 15 341.1±19.5ef 15
SR c 352.5±24.4 10 337.4±20.6 14 362.2±19.9 15 298.4±19.9ce 15
b,c significance levels from multivariate analysis of effect of diagnosis in each layer and of 
planned contrasts within layers: versus controls- b p ≤ 0.05, c p ≤ 0.1; versus MDD- d p ≤
0.01, e p ≤ 0.05; and versus schizophrenia- f p ≤ 0.05. SCZ - Schizophrenia; MDD - Major 
Depressive Disorder; BPD - Bipolar Disorder; N - Number; ML - Molecular Layer; GCL -
Granule Cell Layer; Hil – Hilus; SO - Stratum Oriens; SP – Stratum Pyramidale; SR -
Stratum Radiatum. 
Table 5
